Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma

NCT01535157 is registered in ClinicalTrials.gov with South Plains Oncology Consortium as lead sponsor.

NCT NCT01535157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01535157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of Fenretinide/LXS Oral Powder (NSC 374551) Plus Ketoconazole in Recurrent Ovarian Cancer and Primary Peritoneal Carcinoma
Lead sponsor
South Plains Oncology Consortium
Phase
Phase 1/2
Overall status
Terminated
Start date
February 29, 2012
Completion date
June 30, 2017
Enrollment
12 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer of ovary, cancer of the ovary, ovarian cancer, ovary neoplasms, primary peritoneal carcinoma